Quick Answer
Prelude Therapeutics Inc reported Research And Development Expense of $94.30 million for the year ending 2025.
- Prelude Therapeutics Inc showed a decrease of -20.1% in Research And Development Expense from 2024 to 2025.
- This data is from Prelude Therapeutics Inc's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $5.49 million | Q1 2020: $8.54 million | Q2 2020: $9.78 million | Q3 2020: $15.29 million | Q1 2021: $16.47 million | Q2 2021: $22.41 million | Q3 2021: $22.72 million | Q1 2022: $22.82 million | Q2 2022: $21.31 million | Q3 2022: $22.89 million | Q1 2023: $21.83 million | Q2 2023: $24.97 million | Q3 2023: $26.26 million | Q1 2024: $27.41 million | Q2 2024: $29.51 million | Q3 2024: $29.46 million | Q1 2025: $28.82 million | Q2 2025: $25.78 million | Q3 2025: $21.71 million.
- Over the full 7 years of available data (2019 to 2025), Prelude Therapeutics Inc's Research And Development Expense has grown by 288.4%.
- Historical annual values: Fiscal year 2025: $94.30 million | Fiscal year 2024: $118.00 million | Fiscal year 2023: $103.39 million | Fiscal year 2022: $92.89 million | Fiscal year 2021: $86.78 million | Fiscal year 2020: $48.18 million | Fiscal year 2019: $24.28 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: